Interleukin-6 but not tumour necrosis factor-alpha predicts survival in patients with advanced cancer
| Autor: | Ah Ram Seo, Hong Yup Ahn, Sang Mi Kwak, Myung Ah Lee, Yong Joo Lee, D.G. Kim, Jeanno Park, Eunji Yim, Youn Seon Choi, Chang Hwan Yeom, Su Jin Koh, Sang Yeon Suh, Ho Min Yoon |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Male medicine.medical_specialty Necrosis Cachexia Pain medicine Kaplan-Meier Estimate Tumour necrosis factor alpha Text mining Predictive Value of Tests Risk Factors Internal medicine Neoplasms Republic of Korea medicine Humans In patient Prospective Studies Interleukin 6 Aged Proportional Hazards Models biology business.industry Interleukin-6 Tumor Necrosis Factor-alpha Palliative Care Hospices Middle Aged Prognosis Advanced cancer Anorexia biology.protein Female medicine.symptom business |
| Zdroj: | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 21(11) |
| ISSN: | 1433-7339 |
| Popis: | The purpose of this study was to evaluate the prognostic role of interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in the survival of patients with advanced cancer.In this prospective cohort study between three hospice and palliative care centres in South Korea, we followed 98 advanced cancer patients until death or the end of the study. Approximately 60 % of the patients had poor functional status (Eastern Cooperative Oncology Group score ≥3). We investigated the symptoms of cancer cachexia anorexia syndrome, possible cytokine-related confounders such as infection and medication records. Influence from clinical variables was adjusted using the Cox proportional hazard model.The median survival time was 27 days. On multivariate analysis, elevated IL-6 (hazard ratio, 2.139; p = 0.003) was found to be an independent significant prognostic factor. TNF-α was not a significant factor. Poor performance status and male gender were also independently related to shortened survival.IL-6 level can be a useful indicator of survival time of patients with advanced cancer at the very end of life. In contrast, the prognostic role of TNF-α requires further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink